CRABP2 has been found to facilitate the advancement of gastric cancer, as well as mitigate mitochondrial apoptosis and foster resistance to oxaliplatin in gastric cancer via DNA hydroxymethylation 33. This evidence concerns the gene CRABP2 and gastric cancer.